Pomerantz Law Firm Issues Important Investor Alert on Soleno Therapeutics Class Action Lawsuit

Investor Alert: Soleno Therapeutics Class Action Lawsuit

Pomerantz LLP, a law firm renowned for its extensive history in securities class actions, has recently announced that it has filed a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO). This lawsuit targets individuals who have suffered financial losses due to alleged securities fraud or other illegal business practices by Soleno and its leadership.

Background of the Case

The class action lawsuit is a response to a series of concerning reports about Soleno's only product, diazoxide choline extended-release tablets (DCCR). In August 2025, Scorpion Capital published an alarming report indicating that DCCR was excessively priced and potentially unsafe for pediatric patients. Following this, Soleno's stock value witnessed a significant decline, dropping $5.73 (7.41%) on the same day to close at $71.63.

The situation escalated when, on September 10, 2025, Soleno disclosed to the U.S. Securities and Exchange Commission that a patient had died after taking DCCR. This revelation led to a sharp decrease in share price, where it fell $13.49 (19.21%) over the subsequent trading sessions, culminating in a close of $56.72 on September 11, 2025.

Most recently, during a quarterly earnings call on November 4, 2025, Soleno disclosed a significant discontinuation rate related to adverse effects of DCCR, which stood at approximately 8%. The CEO commented on the disruptions caused by the Scorpion report, indicating that it led to a marked decrease in the initiation of new patient registrations for DCCR.

Implications for Investors

While the legal proceedings unfold, investors who have suffered losses due to these developments are urged to take action. Pomerantz LLP has set a critical deadline of May 5, 2026, for affected investors to request to be appointed as lead plaintiffs in the class action lawsuit. Those interested can reach out to Danielle Peyton at Pomerantz via the provided email or phone number, sharing details, including their contact information and the number of shares purchased.

Why This Matters

Pomerantz LLP is not a newcomer in the realm of class action lawsuits, particularly related to securities. Founded over 85 years ago by Abraham L. Pomerantz, the firm has carved a niche, seeking justice and compensation for victims of corporate misconduct. This recent case against Soleno Therapeutics is just another chapter in the firm’s storied history of advocating for investor rights.

For investors, staying informed about legal proceedings involving their investments is crucial. If you’ve been impacted by the decline of Soleno's stock price and believe you have a case for securities fraud, reaching out to a specialized attorney could potentially result in recovering your losses.

For more information and the full complaint, interested parties can visit Pomerantz's website. Prior case results do not guarantee similar outcomes, and potential plaintiffs are encouraged to act promptly as deadlines approach.

Conclusion

The class action lawsuit against Soleno Therapeutics Inc. highlights significant issues in the pharmaceutical sector, particularly concerning drug safety and pricing. As the situation develops, affected investors must evaluate their options carefully and consider participating in the class action to seek reparations for losses incurred.